Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Yes proto-oncogene 1, Src family tyrosine kinase (YES1) is a non-receptor protein tyrosine kinase of the Src family, encoded by the YES1 gene[1][2][3][7]. YES1 plays a central role in signal transduction, cell growth, cell survival, apoptosis, cell adhesion, cytoskeletal organization, and cell migration by phosphorylating a range of substrates downstream of receptor tyrosine kinases and other signals[1][2][7]. Its dysregulation is implicated in various cancers, where it is considered both a therapeutic target and a potential biomarker for certain tumor types, especially those dependent on Src family kinase signaling[1][6]. Drug targeting of YES1 generally utilizes ATP-competitive tyrosine kinase inhibitors, which can influence both cancer progression and normal physiological processes[6].
Inhibition of tyrosine kinase activity; Blockade of downstream oncogenic signaling pathways; Disruption of cell proliferation and survival pathways
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Yes proto-oncogene 1, Src family tyrosine kinase (YES1).